ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) Starts Presentation at the 2017 Marcum Microcap Conference
ContraVir Pharmaceuticals (NASDAQ: CTRV) is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. One compound, TXL™ is a highly potent analog of the successful antiviral drug Viread® and is currently in phase 2a of development. The company’s other anti-HBV compound, CRV431, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. ContraVir is also developing Valnivudine, an orally available nucleoside analogue prodrug that is currently…







